INMB - INmune Bio - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

INMB is currently covered by 1 analysts with an average price target of $7.76. This is a potential upside of $4.9 (171.33%) from yesterday's end of day stock price of $2.86.

INmune Bio's activity chart (see below) currently has 0 price targets and 3 ratings on display. The stock rating distribution of INMB is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 25% with an average time for these price targets to be met of 161 days.

Highest price target for INMB is $0.6, Lowest price target is $0.6, average price target is $0.6.

Most recent stock forecast was given by GEORGE FARMER from SCOTIABANK on 01-Jul-2025. First documented stock forecast 29-Jan-2021.

Best performing analysts who are covering INMB - INmune Bio:

Chad Mabry Mayank Mamtani Thomas Shrader George Farmer

Currently out of the existing stock ratings of INMB, 3 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$0.6

$-2.13 (-78.02%)

$23

1 months 4 days ago
(01-Jul-2025)

0/3 (0%)

$-1.49 (-71.29%)

Hold

$7

$-2.18 (-23.75%)

$20

3 years 2 months 11 days ago
(24-May-2022)

1/2 (50%)

$1.52 (27.74%)

13

Buy

$14

$4.82 (52.51%)

$31

3 years 2 months 11 days ago
(24-May-2022)

1/2 (50%)

$8.52 (155.47%)

631

Buy

$34

$23.48 (223.19%)

$29

4 years 22 days ago
(14-Jul-2021)

0/2 (0%)

$11.04 (48.08%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is INMB (INmune Bio) average time for price targets to be met?

On average it took 161 days on average for the stock forecasts to be realized with a an average price target met ratio 25

Which analyst has the current highest performing score on INMB (INmune Bio) with a proven track record?

CHAD MABRY

Which analyst has the current lower performing score on INMB (INmune Bio) with a proven track record?

GEORGE FARMER

Which analyst has the most public recommendations on INMB (INmune Bio)?

Chad Mabry has 14 price targets and 8 ratings on INMB

Which analyst is the currently most bullish on INMB (INmune Bio)?

Chad Mabry with highest potential upside - $23.48

Which analyst is the currently most reserved on INMB (INmune Bio)?

Mayank Mamtani with lowest potential downside - -$2.18

INmune Bio in the News

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, August 7th, 2025 at 4:30pm EDT to discuss...

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. Q1 2025 and Recent Corporate Highlights DN-TNF Platform Highlights...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?